Showing results (171-180 of 241) with videos related to

Sort By:
Pageof 25
Oncotarget|May 10, 2014
Unique molecular signatures as a hallmark of patients with metastatic breast cancer: implications for current treatment paradigmsJennifer J Wheler, Barbara A Parker, Jack J Lee, et al.
Cancer|October 21, 2023
Phase 1/2 trial of avelumab combined with utomilumab (4-1BB agonist), PF-04518600 (OX40 agonist), or radiotherapy in patients with advanced gynecologic malignanciesAnne Knisely, Jibran Ahmed, Bettzy Stephen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 16, 2014
Synergy between VEGF/VEGFR inhibitors and chemotherapy agents in the phase I clinicChad Tang, Kenneth Hess, Denis Leonardo F Jardim, et al.
Investigational New Drugs|October 20, 2017
Phase I study of the combination of crizotinib (as a MET inhibitor) and dasatinib (as a c-SRC inhibitor) in patients with advanced cancerShumei Kato, Denis L Jardim, Faye M Johnson, et al.
JCO Precision Oncology|October 31, 2017
Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT): An MD Anderson Precision Medicine StudyApostolia-Maria Tsimberidou, David S Hong, Yang Ye, et al.
The Oncologist|March 30, 2021
Patient-Reported Out-of-Pocket Costs and Financial Toxicity During Early-Phase Oncology Clinical TrialsRyan W Huey, Goldy C George, Penny Phillips, et al.
Cancer Research|May 20, 2016
Cancer Therapy Directed by Comprehensive Genomic Profiling: A Single Center StudyJennifer J Wheler, Filip Janku, Aung Naing, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 29, 2020
Phase I Study of Everolimus, Letrozole, and Trastuzumab in Patients with Hormone Receptor-positive Metastatic Breast Cancer or Other Solid TumorsAlexej Ballhausen, Jennifer J Wheler, Daniel D Karp, et al.
Cancer Medicine|November 25, 2016
Survival of patients with metastatic leiomyosarcoma: the MD Anderson Clinical Center for targeted therapy experienceZhijie Wang, Naiyi Shi, Aung Naing, et al.
Scientific Reports|October 18, 2016
Evaluation of Novel Targeted Therapies in Aggressive Biology Sarcoma Patients after progression from US FDA approved TherapiesVivek Subbiah, Kenneth R Hess, Muhammad Rizwan Khawaja, et al.
Pageof 25